{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:40:27Z","timestamp":1778114427822,"version":"3.51.4"},"reference-count":14,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1016\/j.clinthera.2006.05.016","type":"journal-article","created":{"date-parts":[[2006,7,25]],"date-time":"2006-07-25T07:57:04Z","timestamp":1153814224000},"page":"715-724","source":"Crossref","is-referenced-by-count":42,"title":["Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1080 pg versus Oral transmucosal fentanyl citrate 1600 pg and dose proportionality of FEBT 270 to 1300 \u03bcg: A single-dose, randomized, open-label, three-period study in healthy adult volunteers"],"prefix":"10.1016","volume":"28","author":[{"given":"Mona","family":"Darwish","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Tempero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Kirby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 5","key":"10.1016\/j.clinthera.2006.05.016_bib1","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/j.jpainsymman.2005.01.009","article-title":"Fentanyl","volume":"29","author":"Stanley","year":"2005","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.clinthera.2006.05.016_bib2","first-page":"354","article-title":"Consensus panel recommendations for the assessment and management of breakthrough pain: Part 2 management","volume":"30","author":"Bennett","year":"2005","journal-title":"Pharm Ther"},{"key":"10.1016\/j.clinthera.2006.05.016_bib3","first-page":"54","article-title":"Enhanced buccal delivery of fentanyl using the OraVescent drug delivery system","volume":"1","author":"Pather","year":"2001","journal-title":"Drug Deliv Tech"},{"key":"10.1016\/j.clinthera.2006.05.016_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00137696-200604010-00001","article-title":"Fentanyl effervescent buccal tablets: Enhanced buccal absorption","volume":"4","author":"Durfee","year":"2006","journal-title":"Am J Drug Deliv"},{"key":"10.1016\/j.clinthera.2006.05.016_bib5","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1023\/A:1011936901638","article-title":"Mechanistic studies on effervescent-induced permeability enhancement","volume":"15","author":"Eichman","year":"1998","journal-title":"Pharm Res"},{"key":"10.1016\/j.clinthera.2006.05.016_bib6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0939-6411(97)00099-4","article-title":"The influence of in-vivo carbonation on GI physiological processes and drug permeability","volume":"44","author":"Eichman","year":"1997","journal-title":"Eurj Pharm Biopharm"},{"key":"10.1016\/j.clinthera.2006.05.016_bib7","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0304-3959(91)90181-V","article-title":"An open label study of oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough cancer pain","volume":"45","author":"Fine","year":"1991","journal-title":"Pain"},{"key":"10.1016\/j.clinthera.2006.05.016_bib8","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.2165\/00003088-200544120-00006","article-title":"Pharmacokinetics and dose proportionality of fentanyl effervescent buccal tablets in healthy volunteers","volume":"44","author":"Darwish","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2006.05.016_bib9","series-title":"International Conference on Harmonisation-World Health Organization","author":"European Agency for the Evaluation of Medicinal Products","year":"2002"},{"key":"10.1016\/j.clinthera.2006.05.016_bib10","first-page":"3","article-title":"1983 Metropolitan height and weight tables","volume":"64","year":"1983","journal-title":"Stat Bull Metrop Life Found"},{"key":"10.1016\/j.clinthera.2006.05.016_bib11","series-title":"Actiq (oral transmucosal fentanyl citrate 400 \u03bcg) [product information]","year":"2004"},{"key":"10.1016\/j.clinthera.2006.05.016_bib12","series-title":"Guidance for Industry: Statistical Approaches to Establishing Bioequivalence","author":"US Dept of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research","year":"2005"},{"key":"10.1016\/j.clinthera.2006.05.016_bib13","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1023\/A:1026451721686","article-title":"Confidence interval criteria for assessment of dose proportionality","volume":"17","author":"Smith","year":"2000","journal-title":"Pharm Res"},{"key":"10.1016\/j.clinthera.2006.05.016_bib14","series-title":"Catalog of FDA Approved Drug Products: Actiq (NDA) #020747 Drug Details","author":"US Food and Drug Administration (FDA)","year":"2006"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291806001275?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291806001275?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T17:21:59Z","timestamp":1547486519000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291806001275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["S0149291806001275"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2006.05.016","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2006,5]]}}}